Search - tctmd.com

Displaying 161 - 180 of 318

Sort: Relevancy | Date

News Daily News

Postmenopausal Women See Added ASCVD Risk After Complicated Pregnancies

Caitlin E. Cox

September 18, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

L.A. McKeown

September 03, 2020

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

News Daily News

Early Revascularization in NSTEMI Linked to Lower Mortality: AHRQ Analysis

Michael O'Riordan

August 20, 2020

News Daily News

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Michael O'Riordan

July 14, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

L.A. McKeown

June 08, 2020

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Shelley Wood

March 30, 2020

Presentation ACC 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presenter: William Hiatt

March 29, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

L.A. McKeown

March 20, 2020

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Shelley Wood

February 14, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Todd Neale

February 10, 2020

Advertisement

Postmenopausal Women See Added ASCVD Risk After Complicated Pregnancies

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Early Revascularization in NSTEMI Linked to Lower Mortality: AHRQ Analysis

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Missed Opportunities: Many HF Patients Not Tested for CAD

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Trials of New Cancer Drugs Failing to Address Potential CV Risks

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content